| Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation CN Kotton, D Kumar, AM Caliendo, A Åsberg, S Chou, L Danziger-Isakov, ... Transplantation 96 (4), 333-360, 2013 | 917 | 2013 |
| International consensus guidelines on the management of cytomegalovirus in solid organ transplantation CN Kotton, D Kumar, AM Caliendo, A Åsberg, S Chou, DR Snydman, ... Transplantation 89 (7), 779-795, 2010 | 703 | 2010 |
| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ... Therapeutic drug monitoring 41 (3), 261-307, 2019 | 530 | 2019 |
| Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients A Asberg, A Humar, H Rollag, AG Jardine, H Mouas, MD Pescovitz, ... American Journal of Transplantation 7 (9), 2106-2113, 2007 | 462 | 2007 |
| The european renal association–european dialysis and transplant association (ERA-EDTA) registry annual report 2015: a summary A Kramer, M Pippias, M Noordzij, VS Stel, N Afentakis, PM Ambühl, ... Clinical kidney journal 11 (1), 108-122, 2018 | 451 | 2018 |
| Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients A Asberg, A Humar, AG Jardine, H Rollag, MD Pescovitz, H Mouas, ... American Journal of Transplantation 9 (5), 1205-1213, 2009 | 204 | 2009 |
| Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients A Åsberg Drugs 63, 367-378, 2003 | 194 | 2003 |
| The ERA-EDTA registry annual report 2018: a summary A Kramer, R Boenink, VS Stel, C Santiuste de Pablos, F Tomović, E Golan, ... Clinical kidney journal 14 (1), 107-123, 2021 | 193 | 2021 |
| Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several‐fold in patients with atorvastatin‐induced myopathy M Hermann, MP Bogsrud, E Molden, A Åsberg, BU Mohebi, L Ose, ... Clinical Pharmacology & Therapeutics 79 (6), 532-539, 2006 | 170 | 2006 |
| Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus TAS Halden, KE Kvitne, K Midtvedt, L Rajakumar, I Robertsen, J Brox, ... Diabetes care 42 (6), 1067-1074, 2019 | 165 | 2019 |
| The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients I Lunde, S Bremer, K Midtvedt, B Mohebi, M Dahl, S Bergan, A Åsberg, ... European journal of clinical pharmacology 70, 685-693, 2014 | 157 | 2014 |
| Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin R Amundsen, H Christensen, B Zabihyan, A Åsberg Drug metabolism and disposition 38 (9), 1499-1504, 2010 | 157 | 2010 |
| The European renal association–European dialysis and transplant association registry annual report 2014: a summary M Pippias, A Kramer, M Noordzij, N Afentakis, R Alonso de la Torre, ... Clinical kidney journal 10 (2), 154-169, 2017 | 154 | 2017 |
| Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro IB Skottheim, A Gedde-Dahl, S Hejazifar, K Hoel, A Åsberg European Journal of Pharmaceutical Sciences 33 (4-5), 317-325, 2008 | 151 | 2008 |
| Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients A Åsberg, A Hartmann, E Fjeldså, S Bergan, H Holdaas American Journal of Transplantation 1 (4), 382-386, 2001 | 150 | 2001 |
| Importance of hematocrit for a tacrolimus target concentration strategy E Størset, N Holford, K Midtvedt, S Bremer, S Bergan, A Åsberg European journal of clinical pharmacology 70, 65-77, 2014 | 131 | 2014 |
| Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease O Manuel, A Åsberg, X Pang, H Rollag, VC Emery, JK Preiksaitis, ... Clinical infectious diseases 49 (8), 1160-1166, 2009 | 129 | 2009 |
| Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients HA Myhre, DH Dorenberg, KI Kristiansen, H Rollag, T Leivestad, A Åsberg, ... Transplantation 92 (2), 217-223, 2011 | 128 | 2011 |
| Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects M Ulvestad, IB Skottheim, GS Jakobsen, S Bremer, E Molden, A Åsberg, ... Clinical Pharmacology & Therapeutics 93 (3), 275-282, 2013 | 121 | 2013 |
| Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology S Bergan, M Brunet, DA Hesselink, KL Johnson-Davis, PK Kunicki, ... Therapeutic drug monitoring 43 (2), 150-200, 2021 | 120 | 2021 |
